Targets › E7
5 programs from 4 companies in 7 trials: 6 Phase 1, 1 Phase 2; Oncology, Infectious disease; next expected readout Jan 2027.
Open in Phaseline: the race on E7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Christian Hinrichs | KK-LC-1 TCR-T cells T cell receptor (TCR) engineered to recognize HPV E7 antigen; adoptive cell therapy | E7 | Phase 2 | Cervical Cancer; Gastric Cancer; HPV-Associated Cervical Carcinoma | Jan 2027 |
| Cellid | BVAC-E6E7 HPV E6/E7-targeting immunotherapeutic vaccine | E6, E7 | Phase 1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Mar 2027 |
| University of Alabama at Birmingham | TA-CIN Recombinant fusion protein vaccine comprised of HPV16 L2, E7, and E6 proteins | E6, E7, L2 | Phase 1 | ASC-US | Dec 2027 |
| University of Alabama at Birmingham | pNGVL4aCRTE6E7L2 DNA plasmid vaccine encoding HPV16 E6, E7, and L2 antigens | E6, E7, L2 | Phase 1 | ASC-US | Dec 2027 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | pNGVL4aCRTE6E7L2 HPV16 DNA vaccine encoding E6 and E7 antigens with electroporation delivery | HPV16, E6, E7 | Phase 1 | Human Papillomavirus Type 16 | Dec 2027 |
ASC-US (2) Head and Neck Squamous Cell Carcinoma (HNSCC) (1) Cervical Cancer (1) Gastric Cancer (1) HPV-Associated Cervical Carcinoma (1) Human Papillomavirus Type 16 (1)
protein or peptide (3), mixed (1), small molecule (1)
University of Alabama at Birmingham (2) Cellid (1) Christian Hinrichs (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.